TapewireFind a company

person · Reporting owner

Dulac Edward J III

Disclosed activity across 2 companies

Tapewire entity
28787
SEC CIK
0001821530

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
FATE THERAPEUTICS INCFATE · Entity 5968Chief Financial OfficerMarch 04, 2024March 05, 2024
Intellia Therapeutics, Inc.NTLA · Entity 4585EVP, Chief Financial OfficerJuly 22, 2026July 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

FATE THERAPEUTICS INC

Report date March 04, 2024 · Filed March 05, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect101,479 Reported balance After 2024-03-04 transaction · row 1
1 source row

Row 1 · 2024-03-04 · Sale · Disposed 2,447 · Balance 101,479

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Intellia Therapeutics, Inc.

Report date July 22, 2026 · Filed July 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect148,175 Reported balance After 2026-07-22 transaction · row 1
1 source row

Row 1 · 2026-07-22 · Sale · Disposed 8,111 · Balance 148,175

F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 22, 2026 Filed Jul 24, 2026 21:26 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 SaleCommon Stock 8,111 $11.25 $91,248.75
Disclosure

SEC source: 0001193125-26-316279 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,175

F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.

Read SEC document
July 02, 2026 Filed Jul 6, 2026 21:01 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 SaleCommon Stock 4,677 $18.00 $84,186.00
Disclosure

SEC source: 0001821530-26-000002 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,286

F1 · kind: The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:17 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantStock Option (right to buy) · Derivative 87,543 $0.00 Strike: $13.78 $0.00
Disclosure

SEC source: 0001193125-26-088254 · ownership.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,543

Underlying: Common Stock · 87,543 shares

Expires 2036-02-29

F2 · derivative.exercise_date: This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:17 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantCommon Stock 61,280 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-088254 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,963

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 21:02 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 SaleCommon Stock 6,379 $9.21 $58,750.59
Disclosure

SEC source: 0001193125-26-006275 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,683

F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

Read SEC document
July 23, 2025 Filed Jul 25, 2025 20:05 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 SaleCommon Stock 7,462 $14.02 $104,617.24
Disclosure

SEC source: 0000950170-25-098774 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,062

F1 · kind: Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 21:34 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantStock Option (right to buy) · Derivative 67,429 $0.00 Strike: $10.09 $0.00
Disclosure

SEC source: 0000950170-25-032192 · ownership.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,429

Underlying: Common Stock · 67,429 shares

Expires 2035-02-28

F2 · derivative.exercise_date: This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 21:34 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantCommon Stock 47,200 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032192 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,524

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:17 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantStock Option (right to buy) · Derivative 96,219 $0.00 Strike: $25.33 $0.00
Disclosure

SEC source: 0000950170-24-086061 · ownership.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,219

Underlying: Common Stock · 96,219 shares

Expires 2034-07-21

F2 · derivative.exercise_date: This option was granted on July 22, 2024 with respect to shares of Common Stock, with 33% vesting on July 22, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Read SEC document
July 22, 2024 Filed Jul 24, 2024 20:17 UTC Intellia Therapeutics, Inc. NTLA · Entity 4585 GrantCommon Stock 66,324 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-086061 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,324

F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:24 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 2,447 $7.77 $19,013.19
Disclosure

SEC source: 0000950170-24-025992 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,479

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Read SEC document
February 01, 2024 Filed Feb 2, 2024 21:09 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantStock Option (Right to Buy) · Derivative 425,000 $0.00 Strike: $6.76 $0.00
Disclosure

SEC source: 0000950170-24-010485 · ownership.xml · derivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 425,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Read SEC document
January 29, 2024 Filed Jan 30, 2024 21:01 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 1,849 $5.00 $9,245.00
Disclosure

SEC source: 0000950170-24-008803 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,926

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:29 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 7,028 $4.37 $30,712.36
Disclosure

SEC source: 0000950170-24-003647 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,775

F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Read SEC document
January 02, 2024 Filed Jan 3, 2024 21:03 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 5,182 $3.66 $18,966.12
Disclosure

SEC source: 0000950170-24-000874 · ownership.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,803

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Read SEC document
December 18, 2023 Filed Dec 19, 2023 21:01 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 1,585 $3.50 $5,547.50
Disclosure

SEC source: 0001209191-23-059103 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,985

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Read SEC document
August 18, 2023 Filed Aug 21, 2023 20:02 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 4,718 $2.80 $13,210.40
Disclosure

SEC source: 0001209191-23-046691 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,570

F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold from $2.76 to $2.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Read SEC document
July 05, 2023 Filed Jul 6, 2023 21:18 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 5,182 $4.83 $25,029.06
Disclosure

SEC source: 0001209191-23-041607 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,288

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023.

Read SEC document
February 06, 2023 Filed Feb 7, 2023 21:15 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantStock Option (Right to Buy) · Derivative 425,000 $0.00 Strike: $6.77 $0.00
Disclosure

SEC source: 0001209191-23-007503 · doc4.xml · derivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 425,000 shares

Expires 2033-02-05

F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Read SEC document
January 10, 2023 Filed Jan 11, 2023 21:06 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 7,331 $5.24 $38,414.44
Disclosure

SEC source: 0001209191-23-002975 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,470

F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

Read SEC document
August 18, 2022 Filed Aug 19, 2022 22:58 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 432 $30.41 $13,137.12
Disclosure

SEC source: 0001209191-22-046929 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,801

F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
August 18, 2022 Filed Aug 19, 2022 22:58 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 4,703 $29.75 $139,914.25
Disclosure

SEC source: 0001209191-22-046929 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,233

F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold from $29.29 to $30.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.

Read SEC document
January 25, 2022 Filed Jan 27, 2022 21:35 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantStock Option (Right to Buy) · Derivative 53,058 $0.00 Strike: $39.87 $0.00
Disclosure

SEC source: 0000899243-22-003443 · doc4.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,058

Underlying: Common Stock · 53,058 shares

Expires 2032-01-24

F2 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.

Read SEC document
January 25, 2022 Filed Jan 27, 2022 21:35 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantCommon Stock 33,302 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-003443 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,936

F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:06 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 390 $49.16 $19,172.40
Disclosure

SEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,634

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.83 to $49.31 per share.

Read SEC document
January 11, 2022 Filed Jan 13, 2022 21:06 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 1,380 $48.25 $66,585.00
Disclosure

SEC source: 0001209191-22-003168 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,024

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.71 to $48.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3.

Read SEC document
December 20, 2021 Filed Dec 21, 2021 21:08 UTC FATE THERAPEUTICS INC FATE · Entity 5968 Exercise / conversionStock Option (Right to Buy) · Derivative 14,437 $0.00 Strike: $35.52 $0.00
Disclosure

SEC source: 0001209191-21-070768 · doc4.xml · derivative · entry 3

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,238

Underlying: Common Stock · 14,437 shares

Expires 2030-08-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Read SEC document
December 20, 2021 Filed Dec 21, 2021 21:08 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 15,977 $60.00 $958,620.00
Disclosure

SEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,404

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

Read SEC document
December 20, 2021 Filed Dec 21, 2021 21:08 UTC FATE THERAPEUTICS INC FATE · Entity 5968 Exercise / conversionCommon Stock 14,437 $35.52 $512,802.24
Disclosure

SEC source: 0001209191-21-070768 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

Read SEC document
November 19, 2021 Filed Nov 22, 2021 22:41 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantCommon Stock 59,540 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-066159 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,944

F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

Read SEC document
September 28, 2021 Filed Sep 30, 2021 20:14 UTC FATE THERAPEUTICS INC FATE · Entity 5968 Exercise / conversionStock Option (Right to Buy) · Derivative 17,325 $0.00 Strike: $35.52 $0.00
Disclosure

SEC source: 0001209191-21-058176 · doc4.xml · derivative · entry 3

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,675

Underlying: Common Stock · 17,325 shares

Expires 2030-08-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Read SEC document
September 28, 2021 Filed Sep 30, 2021 20:14 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 19,460 $62.53 $1,216,833.80
Disclosure

SEC source: 0001209191-21-058176 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,404

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

Read SEC document
September 28, 2021 Filed Sep 30, 2021 20:14 UTC FATE THERAPEUTICS INC FATE · Entity 5968 Exercise / conversionCommon Stock 17,325 $35.52 $615,384.00
Disclosure

SEC source: 0001209191-21-058176 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.

Read SEC document
August 19, 2021 Filed Aug 20, 2021 20:01 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 63 $90.00 $5,670.00
Disclosure

SEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 3

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,539

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Read SEC document
August 19, 2021 Filed Aug 20, 2021 20:01 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 1,474 $88.65 $130,670.10
Disclosure

SEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,602

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.47 to $89.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 19, 2021 Filed Aug 20, 2021 20:01 UTC FATE THERAPEUTICS INC FATE · Entity 5968 SaleCommon Stock 1,937 $87.90 $170,262.30
Disclosure

SEC source: 0001209191-21-052742 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,076

F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the reporting person on August 17, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.42 to $88.33 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 20, 2021 Filed Jan 22, 2021 23:18 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantStock Option (right to buy) · Derivative 6,851 Not disclosed Strike: $109.01 Not disclosed
Disclosure

SEC source: 0001209191-21-004953 · doc4.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,851

Underlying: Common Stock · 6,851 shares

Expires 2031-01-20

F3 · price: Not applicable.

F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025.

Read SEC document
January 20, 2021 Filed Jan 22, 2021 23:18 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantCommon stock 18,013 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-004953 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,013

F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025.

Read SEC document
August 17, 2020 Filed Aug 19, 2020 20:12 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantStock Option (right to buy) · Derivative 160,000 $0.00 Strike: $35.52 $0.00
Disclosure

SEC source: 0001209191-20-047483 · doc4.xml · derivative · entry 2

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2030-08-17

F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on the first anniversary of the grant date and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Read SEC document
August 17, 2020 Filed Aug 19, 2020 20:12 UTC FATE THERAPEUTICS INC FATE · Entity 5968 GrantCommon stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-047483 · doc4.xml · nonDerivative · entry 1

Dulac Edward J III · CIK 0001821530 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Exempt grant of restricted stock units pursuant to the Issuer's Inducement Equity Plan. The units will vest in four annual installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.